Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPYY5 receptor antagonists

被引：19

作者：

Ogino, Yoshio ^{[1
]}

Ohtake, Norikazu ^{[1
]}

Nagae, Yoshikazu ^{[1
]}

Matsuda, Kenji ^{[1
]}

Ishikawa, Makoto ^{[1
]}

Moriya, Minoru ^{[1
]}

Kanesaka, Maki ^{[1
]}

Mitobe, Yuko ^{[1
]}

Ito, Junko ^{[1
]}

Kanno, Tetsuya ^{[1
]}

Ishihara, Akane ^{[1
]}

Iwaasa, Hisashi ^{[1
]}

Ohe, Tomoyuki ^{[1
]}

Kanatani, Akio ^{[1
]}

Fukami, Takehiro ^{[1
]}

机构：

[1] Banyu Pharmaceut Co Ltd, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 18期

关键词：

neuropeptide Y; Y5; receptor; antagonist; anti-obesity; benzimidazole;

D O I：

10.1016/j.bmcl.2008.08.021

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Syntheses and structure-activity relationships of a novel class of 2-[3-oxospiro[isobenzofuran-1(3H), 1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists are described. Optimization of the lead compound 2a by incorporating substituents into the 5-position or into both the 5-and 6-positions of the benzimidazole core part led to the identification of 5-(5-methyl-1,2,4-oxadiazol-2-yl) benzimidazole (2r: IC(50) = 3.3 nM) and 5-(2-methyltetrazol-5-yl) benzimidazole (2u: IC(50) = 5.9 nM), both of which are potent, selective, and orally bioavailable Y5 receptor antagonists. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.

引用

页码：4997 / 5001

页数：5

共 50 条

[21] Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists
Müller, CE
Geis, U
Hipp, J
Schobert, U
Frobenius, W
Pawlowski, M
Suzuki, F
Sandoval-Ramírez, J
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (26) : 4396 - 4405
[22] Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors
Sanchez, Robert M.
Erhard, Karl
Hardwicke, Mary Ann
Lin, Hong
McSurdy-Freed, Jeanelle
Plant, Ramona
Raha, Kaushik
Rominger, Cynthia M.
Schaber, Michael D.
Spengler, Michael D.
Moore, Michael L.
Yu, Hongyi
Luengo, Juan I.
Tedesco, Rosanna
Rivero, Ralph A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (09) : 3198 - 3202
[23] Novel AMPA receptor antagonists: Synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)-quinoxalinedione and related compounds
Ohmori, J
ShimizuSasamata, M
Okada, M
Sakamoto, S
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) : 3971 - 3979
[24] 1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structure-Activity Relationships and Identification of Potent and Selective iGluR5 Modulators
Butini, Stefania
Pickering, Darryl S.
Morelli, Elena
Coccone, Salvatore Sanna
Trotta, Francesco
De Angelis, Meri
Guarino, Egeria
Fiorini, Isabella
Campiani, Giuseppe
Novellino, Ettore
Schousboe, Arne
Christensen, Jeppe K.
Gemma, Sandra
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (20) : 6614 - 6618
[25] Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes: Novel and highly potent antagonists for NMDA receptor glycine site
Cai, SX
Zhou, ZL
Huang, JC
Whittemore, ER
Egbuwoku, ZO
Lu, YX
Hawkinson, JE
Woodward, RM
Weber, E
Keana, JFW
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (17) : 3248 - 3255
[26] Novel, Potent, and Selective Quinoxaline-Based 5-HT3 Receptor Ligands. 1. Further Structure-Activity Relationships and Pharmacological Characterization
Butini, Stefania
Budriesi, Roberta
Hamon, Michel
Morelli, Elena
Gemma, Sandra
Brindisi, Margherita
Borrelli, Giuseppe
Novellino, Ettore
Fiorini, Isabella
Ioan, Pierfranco
Chiarini, Alberto
Cagnotto, Alfredo
Mennini, Tiziana
Fracasso, Claudia
Caccia, Silvio
Campiani, Giuseppe
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (21) : 6946 - 6950
[27] Diastereoselective synthesis of trans-2-(1-triphenylmethyl-1H-imidazol-4-yl)cyclopropanecarboxylic acids:: Key intermediates for the preparation of potent and chiral histamine H3 receptor agents
Khan, MA
Yates, SL
Tedford, CE
Kirschbaum, K
Phillips, JG
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (23) : 3017 - 3022
[28] DEVELOPMENT OF POTENT SEROTONIN-3 (5-HT3) RECEPTOR ANTAGONISTS .2. STRUCTURE-ACTIVITY-RELATIONSHIPS OF N-(1-BENZYL-4-METHYLHEXAHYDRO-1H-1,4-DIAZEPIN-6-YL)CARBOXAMIDES
HARADA, H
MORIE, T
HIROKAWA, Y
TERAUCHI, H
FUJIWARA, I
YOSHIDA, N
KATO, S
CHEMICAL & PHARMACEUTICAL BULLETIN, 1995, 43 (11) : 1912 - 1930
[29] Spiro-substituted piperidines as neurokinin receptor antagonists.: I.: Design and synthesis of (±)-N-[2-(3,4-dichlorophenyl)-4-(spiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl)butyl]-N-methylbenzamide, YM-35375, as a new lead compound for novel neurokinin receptor antagonists
Kubota, H
Fujii, M
Ikeda, K
Takeuchi, M
Shibanuma, T
Isomura, Y
CHEMICAL & PHARMACEUTICAL BULLETIN, 1998, 46 (02) : 351 - 354
[30] Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyllpiperazines, novel potential Antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition
Smid, P
Coolen, HKAC
Keizer, HG
van Hes, R
de Moes, JP
den Hartog, AP
Stork, B
Plekkenpol, RH
Niemann, LC
Stroomer, CNJ
Tulp, MTM
van Stuivenberg, HH
McCreary, AC
Hesselink, MB
Herremans, AHJ
Kruse, CG
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) : 6855 - 6869

← 1 2 3 4 5 →